Progress of lysine-specific demethylase 1 and its inhibitors in triple-negative breast cancer
10.3760/cma.j.cn115355-20230625-00329
- VernacularTitle:赖氨酸特异性去甲基化酶1及其抑制剂在三阴性乳腺癌中的研究进展
- Author:
Xunyi LIN
1
;
Hang SU
;
Jiaxing HUO
;
Fenghua ZHANG
Author Information
1. 河北省人民医院腺体外科，石家庄 050051
- Keywords:
Lysine specific demethylase 1;
Breast neoplasms;
Neoadjuvant therapy;
Treatment outcome
- From:
Cancer Research and Clinic
2024;36(1):69-73
- CountryChina
- Language:Chinese
-
Abstract:
Lysine-specific demethylase 1 (LSD1) is the firstly discovered histone demethylase. In recent years, LSD1 has become a hot topic in the study of the development and progression of malignancies, and its expression is closely related to the poor prognosis of malignancies. At present, some studies have showed that LSD1 is strongly related to the proliferation, invasion and metastasis of triple-negative breast cancer (TNBC). However, the specific mechanism is not fully understood. This article summarizes the possible mechanism of the development and progression in LSD1 and TNBC, and reviews the latest progress of LSD1 in the clinical research application of TNBC, so as to provide a reference for drug combination therapy in TNBC patients.
